Table 2.

Monoclonal antibodies approved for ovarian cancer treatment

Name	Antibody	FDA approval	EMA approval	NICE approval
Catumaxumab	EpCAM and CD3 bispecific trAb	–	Treatment of EpCAM-positive ascites	Treatment of EpCAM-positive ascites
Bevacizumab	VEGF-A-specific humanized IgG1	Treatment of platinum-resistant OC	Treatment of ovarian neoplasms	i. In combination with carboplatin and paclitaxel for the treatment of advanced EOC ii. In combination with carboplatin and gemcitabine for first recurrence of platinum-sensitive EOC, FTC or PPC in patients not previously treated with bevacizumab or other VEGF-targeting agents.

FDA, US Food and Drug Administration, www.fda.gov; EMA, European Medicines Agency, www.ema.europa.eu/ema; NICE, UK National Institute for Health and Care Excellence, nice.org.uk; trAb, trifunctional antibody; OC, ovarian carcinoma; EOC, epithelial ovarian cancer; FTC, fallopian tube cancer; PPC, primary peritoneal cancer.